VICH Topic GL9 (GCP)
The European Agency for the Evaluation of MedicinalProductsVeterinary Medicines and Information Technology Unit7 W estferry Circus, Canary W harf, London E14 4HB, UKSwitchboard (44-20) 74 18 84 00 Fax (44-20) 74 18 84 47E-mail: 2000Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA isacknowledgedCVMP/VICH/595/98-FINALLond on, 4 July2000VICH Topic GL9 (GCP) Step 7 Consensus GuidelineGUIDELINE ON GOOD CLINICAL PRACTICESTRANSMISSION TO CVMPDecember 1998TRANSMISSION TO INTERESTED PARTIESDecember 1998COMMENTS REQUESTED BEFOREMay 1999FINAL APPROVAL BY CVMPJuly 2000DATE FOR COMING INTO OPERATION BYJuly 2001FOR IMPLEMENTATION AT STEP 7 (FINAL) 06/00Page 1 of 27EMEA 2000VICH GL9 (GCP)June 2000For Implementation at Step 7GGGGOOD CCCCLINICAL PPPPRACTICERecommended for Implementationat Step 7 of the VICH Processon 15 June 2000by the VICH Steering CommitteeTHISGUIDELINE HAS BEEN DEVELOPED BY THE APPROPRIATEVICH EXPERTWORKINGGROUP AND HASBEEN SUBJECT TO CONSULTATION BY THE PARTIES,IN ACCORDANCE W ITH THEVICH THEPROCESS THE FINAL DRAFT IS RECOMMENDED FOR ADOPTION TO THE REGULATORY BODIES OFTHEEUROPEANUNION,JAPAN IMPLEMENTATION AT STEP 7 (FINAL) 06/00Page 2 of 27EMEA 2000Good Clinical PracticeINTRODUCTIONThe objective of this document is to
A copy, which is a complete reflection of an original document, that bears or contains a statement, signed and dated by the individual(s) making the copy, certifying that such copy is complete and accurate. 1.5. Blinding (Masking) A procedure to reduce potential study bias in which designated study personnel
Download VICH Topic GL9 (GCP)
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: